


PHARMACEUTICAL 2017

SOLIGENIX INC. Rank 110 of 313







PHARMACEUTICAL 2017

SOLIGENIX INC. Rank 110 of 313



The relative strengths and weaknesses of SOLIGENIX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SOLIGENIX INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 610% points. The greatest weakness of SOLIGENIX INC. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 491% points.

The company's Economic Capital Ratio, given in the ranking table, is -77%, being 340% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	10,114
Cost of Goods Sold	8,434
Intangible Assets	127
Liabilities, Current	2,870
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	-530
Other Liabilities	0
Other Net Income	1,934
Property and Equipment	27
Research and Development	4,296
Revenues	10,449
Selling, General and Administrative Expense	3,429

Output Variable	Value in 1000 USD
Assets	10,267
Liabilities	2,870
Expenses	15,628
Stockholders Equity	7,397
Net Income	-3,245
Comprehensive Net Income	-3,245
Economic Capital Ratio	-77%